(Q43237169)

17 November 2017

title

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder (English)

1 reference

17 November 2017

1 reference

placebo-controlled trial

1 reference

Roger R Dmochowski

1

1 reference

17 November 2017

Kenneth M Peters

2

1 reference

17 November 2017

Jon D Morrow

3

1 reference

17 November 2017

Zhonghong Guan

4

1 reference

17 November 2017

Jason Gong

5

1 reference

17 November 2017

Franklin Sun

6

1 reference

17 November 2017

Paul Siami

7

1 reference

17 November 2017

David R Staskin

8

1 reference

17 November 2017

language of work or name

English

0 references

publication date

22 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

75

1 reference

17 November 2017

issue

1

1 reference

17 November 2017

page(s)

62-68

1 reference

Reviewing the ICS 2002 terminology report: The ongoing debate

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Prevalence and burden of overactive bladder in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Impact of fesoterodine on quality of life: pooled data from two randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Validation of the urgency perception scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Determining the importance of change in the overactive bladder questionnaire.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Fesoterodine dose response in subjects with overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

Muscarinic receptor antagonists for overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.09.018

10.1016/J.UROLOGY.2009.09.018

7 January 2021

Identifiers

DOI

1 reference

17 November 2017

1 reference